Brown R S, Leung J Y, Kison P V, Zasadny K R, Flint A, Wahl R L
Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor 48109-0028, USA.
J Nucl Med. 1999 Apr;40(4):556-65.
PET imaging of malignant tumors with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) as a tracer is a noninvasive diagnostic and prognostic tool that measures tumor metabolism. In this study, we assessed the relationships between FDG uptake and the expression of facilitative glucose transporters, the sizes of populations of proliferating cells and infiltrating macrophages in patients with primary non-small cell lung cancers (NSCLC).
FDG uptake and the expression of five glucose transporters and the proportions of proliferating cell and macrophage populations were studied in paraffin sections from untreated primary lung cancers by immunohistochemistry. The patients were imaged with FDG PET before surgery.
All tumors could be detected by FDG PET. Uptake was correlated with tumor size (P = 0.004). FDG uptake was lower in adenocarcinomas (ACs) than in squamous cell carcinomas (SQCs) (P = 0.03) or large cell carcinomas (P = 0.002) [standardized uptake value corrected for lean body mass (SUL) = 5.42 +/- 2.77, 8.04 +/-3.25 and 10.42 +/- 4.54, respectively]. Glut-1 expression was significantly higher than that of any other transporter. All tumors tested (n = 23) were Glut-1-positive (70.8% +/- 26.1% of tumor cell area was positive and staining intensity was 2.8 +/- 1.2). Glut-1 expression was higher in SQCs (78% +/- 17.8% and 3.5 +/-0.6) than in ACs (47.5% +/- 30.3% and 1.6 +/- 1.1; P = 0.044 for positive tumor cell area and P = 0.005 for staining intensity). Proliferating cells constituted 15.3% +/- 13.1% of the cancer cells, and the average number of macrophages was 7.8% +/- 6.3%; neither correlated with FDG uptake.
In this population of patients with NSCLC, Glut-1 is the major glucose transporter expressed. Both FDG uptake and Glut-1 expression appear to be associated with tumor size. No association was found between FDG uptake and either macrophage or proliferative cell populations.
以2-[氟-18]-氟-2-脱氧-D-葡萄糖（FDG）作为示踪剂对恶性肿瘤进行PET成像，是一种测量肿瘤代谢的非侵入性诊断和预后工具。在本研究中，我们评估了原发性非小细胞肺癌（NSCLC）患者中FDG摄取与易化葡萄糖转运蛋白表达、增殖细胞群体大小和浸润巨噬细胞之间的关系。
通过免疫组织化学研究未经治疗的原发性肺癌石蜡切片中FDG摄取、五种葡萄糖转运蛋白的表达以及增殖细胞和巨噬细胞群体的比例。患者在手术前进行FDG PET成像。
FDG PET可检测到所有肿瘤。摄取与肿瘤大小相关（P = 0.004）。腺癌（AC）中的FDG摄取低于鳞状细胞癌（SQC）（P = 0.03）或大细胞癌（P = 0.002）[经瘦体重校正的标准化摄取值（SUL）分别为5.42±2.77、8.04±3.25和10.42±4.54]。Glut-1的表达显著高于任何其他转运蛋白。所有检测的肿瘤（n = 23）均为Glut-1阳性（肿瘤细胞面积的70.8%±26.1%为阳性，染色强度为2.8±1.2）。SQC中Glut-1的表达（78%±17.8%和3.5±0.6）高于AC（47.5%±30.3%和1.6±1.1；阳性肿瘤细胞面积P = 0.044，染色强度P = 0.005）。增殖细胞占癌细胞的15.3%±13.1%，巨噬细胞的平均数量为7.8%±6.3%；两者均与FDG摄取无关。
在这群NSCLC患者中，Glut-1是主要表达的葡萄糖转运蛋白。FDG摄取和Glut-1表达似乎均与肿瘤大小有关。未发现FDG摄取与巨噬细胞或增殖细胞群体之间存在关联。
